PT1976880T - Composições farmacêuticas com resistência a cea solúvel - Google Patents
Composições farmacêuticas com resistência a cea solúvelInfo
- Publication number
- PT1976880T PT1976880T PT68411123T PT06841112T PT1976880T PT 1976880 T PT1976880 T PT 1976880T PT 68411123 T PT68411123 T PT 68411123T PT 06841112 T PT06841112 T PT 06841112T PT 1976880 T PT1976880 T PT 1976880T
- Authority
- PT
- Portugal
- Prior art keywords
- resistance
- pharmaceutical compositions
- soluble cea
- cea
- soluble
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Cephalosporin Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75196305P | 2005-12-21 | 2005-12-21 | |
EP05028064 | 2005-12-21 | ||
US78086106P | 2006-03-10 | 2006-03-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT1976880T true PT1976880T (pt) | 2016-09-28 |
Family
ID=40413962
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT68411123T PT1976880T (pt) | 2005-12-21 | 2006-12-21 | Composições farmacêuticas com resistência a cea solúvel |
Country Status (25)
Country | Link |
---|---|
US (3) | US8394926B2 (pt) |
EP (2) | EP2527370A1 (pt) |
JP (2) | JP5399712B2 (pt) |
KR (1) | KR101287777B1 (pt) |
CN (1) | CN101370827B (pt) |
AU (1) | AU2006328886C1 (pt) |
BR (1) | BRPI0620632A2 (pt) |
CA (1) | CA2633766C (pt) |
CY (1) | CY1118053T1 (pt) |
DK (1) | DK1976880T3 (pt) |
ES (1) | ES2595091T3 (pt) |
HK (1) | HK1115890A1 (pt) |
HR (1) | HRP20161216T1 (pt) |
HU (1) | HUE031151T2 (pt) |
IL (1) | IL192277A (pt) |
LT (1) | LT1976880T (pt) |
ME (1) | ME02581B (pt) |
NZ (1) | NZ569204A (pt) |
PL (1) | PL1976880T3 (pt) |
PT (1) | PT1976880T (pt) |
RS (1) | RS55181B1 (pt) |
RU (2) | RU2426743C2 (pt) |
SG (1) | SG193141A1 (pt) |
WO (1) | WO2007071426A1 (pt) |
ZA (1) | ZA200805400B (pt) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
KR20130019457A (ko) | 2004-07-26 | 2013-02-26 | 다우 글로벌 테크놀로지스 엘엘씨 | 균주 조작에 의한 개선된 단백질 발현 방법 |
JP5463036B2 (ja) * | 2005-12-21 | 2014-04-09 | アムゲン リサーチ (ミュンヘン) ゲーエムベーハー | 可溶性ceaに対する抵抗性を有する医薬抗体組成物 |
DK1976880T3 (en) | 2005-12-21 | 2016-09-26 | Amgen Res (Munich) Gmbh | Pharmaceutical compositions with resistance to soluble cea |
US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
CN101688213A (zh) | 2007-04-27 | 2010-03-31 | 陶氏环球技术公司 | 用于快速筛选微生物宿主以鉴定某些在表达异源蛋白质方面具有改善的产量和/或质量的菌株的方法 |
JP5490714B2 (ja) * | 2007-11-28 | 2014-05-14 | メディミューン,エルエルシー | タンパク質製剤 |
GB0908613D0 (en) * | 2009-05-20 | 2009-06-24 | Immunocore Ltd | T Cell Reseptors |
CA2774260C (en) | 2009-09-16 | 2018-10-09 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
AU2010326174A1 (en) * | 2009-12-01 | 2012-07-12 | Medimmune, Llc | Improved methods and compositions for detecting and treating CEA-expressing cancers |
WO2012097313A2 (en) | 2011-01-14 | 2012-07-19 | The Regents Of The University Of California | Therapeutic antibodies against ror-1 protein and methods for use of same |
WO2013012414A1 (en) * | 2011-07-18 | 2013-01-24 | Medimmune, Llc | Dosing regimens for treatment of cea-expressing cancers |
WO2013054320A1 (en) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
US9783610B2 (en) | 2012-04-27 | 2017-10-10 | The Trustees Of The University Of Pennsylvania | Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof |
WO2013174404A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
US20150231241A1 (en) | 2012-08-14 | 2015-08-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
US9315567B2 (en) | 2012-08-14 | 2016-04-19 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
WO2014075788A1 (en) | 2012-11-13 | 2014-05-22 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
WO2014079886A1 (en) | 2012-11-20 | 2014-05-30 | Sanofi | Anti-ceacam5 antibodies and uses thereof |
MY192312A (en) * | 2013-02-26 | 2022-08-17 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
RU2015140915A (ru) | 2013-02-26 | 2017-04-03 | Роше Гликарт Аг | Биспецифические антигенсвязывающие молекулы, активирующие т-клетки |
AR095596A1 (es) | 2013-03-15 | 2015-10-28 | Amgen Res (Munich) Gmbh | Moléculas de unión de cadena única comprendiendo n-terminal abp |
EP2930188A1 (en) * | 2014-04-13 | 2015-10-14 | Affimed Therapeutics AG | Trifunctional antigen-binding molecule |
US11427647B2 (en) | 2014-04-27 | 2022-08-30 | Famewave Ltd. | Polynucleotides encoding humanized antibodies against CEACAM1 |
EP3137502B1 (en) | 2014-04-27 | 2020-07-29 | FameWave Ltd. | Humanized antibodies against ceacam1 |
SG11201609707WA (en) | 2014-07-01 | 2017-01-27 | Pfizer | Bispecific heterodimeric diabodies and uses thereof |
CN107580603A (zh) | 2015-02-24 | 2018-01-12 | 生物蛋白有限公司 | 条件活性生物蛋白 |
CN106432502B (zh) * | 2015-08-10 | 2020-10-27 | 中山大学 | 用于治疗cea阳性表达肿瘤的双特异纳米抗体 |
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
CN107849137B (zh) | 2015-10-02 | 2021-11-26 | 豪夫迈·罗氏有限公司 | 双特异性抗ceaxcd3 t细胞活化性抗原结合分子 |
JP7325186B2 (ja) | 2015-12-09 | 2023-08-14 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 抗薬物抗体の形成を減少させるためのii型抗cd20抗体 |
MX2018008347A (es) | 2016-01-08 | 2018-12-06 | Hoffmann La Roche | Metodos de tratamiento de canceres positivos para ace utilizando antagonistas de union a eje pd-1 y anticuerpos biespecificos anti-ace/anti-cd3. |
WO2017208018A1 (en) | 2016-06-02 | 2017-12-07 | Immunocore Limited | Dosing regimen for gp100-specific tcr - anti-cd3 scfv fusion protein |
CN107663240B (zh) * | 2016-07-29 | 2021-01-12 | 中国人民解放军第四军医大学 | 高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用 |
CN110087682B (zh) | 2016-12-19 | 2023-12-15 | 豪夫迈·罗氏有限公司 | 用靶向性4-1bb(cd137)激动剂的组合疗法 |
BR112019013189A2 (pt) | 2017-01-03 | 2019-12-10 | Hoffmann La Roche | moléculas de ligação ao antígeno biespecífica, polinucleotídeo, célula hospedeira, método de produção da molécula de ligação ao antígeno biespecífica, composição farmacêutica, uso, métodos para inibir o crescimento de células tumorais em um indivíduo e para tratar o câncer ou uma doença infecciosa |
CN107056952A (zh) * | 2017-05-10 | 2017-08-18 | 常州市第人民医院 | Cea.car‑t及其制备与应用 |
CN107058234B (zh) * | 2017-05-12 | 2019-09-13 | 常州市第一人民医院 | Car.il-33-t及其制备与应用 |
CN113896797B (zh) | 2017-08-01 | 2023-05-09 | Ab工作室有限公司 | 双特异性抗体及其用途 |
CA3079036A1 (en) | 2017-11-01 | 2019-05-09 | F. Hoffmann-La Roche Ag | Combination therapy with targeted ox40 agonists |
EP3502140A1 (en) | 2017-12-21 | 2019-06-26 | F. Hoffmann-La Roche AG | Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules |
US20210221908A1 (en) | 2018-06-03 | 2021-07-22 | Lamkap Bio Beta Ltd. | Bispecific antibodies against ceacam5 and cd47 |
EP3818082A1 (en) | 2018-07-04 | 2021-05-12 | F. Hoffmann-La Roche AG | Novel bispecific agonistic 4-1bb antigen binding molecules |
MY198034A (en) | 2018-12-21 | 2023-07-27 | Hoffmann La Roche | Tumor-targeted agonistic cd28 antigen binding molecules |
US20220080053A1 (en) | 2019-02-07 | 2022-03-17 | Sanofi | Use of anti-ceacam5 immunoconjugates for treating lung cancer |
EP3693023A1 (en) | 2019-02-11 | 2020-08-12 | Sanofi | Use of anti-ceacam5 immunoconjugates for treating lung cancer |
KR102503349B1 (ko) | 2019-05-14 | 2023-02-23 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
CA3142887A1 (en) | 2019-06-13 | 2020-12-17 | Bolt Biotherapeutics, Inc. | Aminobenzazepine compounds, immunoconjugates, and uses thereof |
WO2020260326A1 (en) | 2019-06-27 | 2020-12-30 | F. Hoffmann-La Roche Ag | Novel icos antibodies and tumor-targeted antigen binding molecules comprising them |
WO2021041300A2 (en) * | 2019-08-23 | 2021-03-04 | Ab Therapeutics, Inc. | Bispecific antibodies and uses thereof |
CN114630684A (zh) | 2019-09-03 | 2022-06-14 | 博尔特生物治疗药物有限公司 | 氨基喹啉化合物、免疫缀合物及其用途 |
CN114786776A (zh) | 2019-09-18 | 2022-07-22 | 拉姆卡普生物阿尔法股份公司 | 针对ceacam5和cd3的双特异性抗体 |
AU2020359446A1 (en) | 2019-09-30 | 2022-04-21 | Bolt Biotherapeutics, Inc. | Amide-linked, aminobenzazepine immunoconjugates, and uses thereof |
TW202128226A (zh) | 2019-10-25 | 2021-08-01 | 美商博特生物治療公司 | 噻吩并氮呯免疫結合物及其用途 |
WO2021098822A1 (zh) * | 2019-11-21 | 2021-05-27 | 江苏恒瑞医药股份有限公司 | 一种双特异性抗体 |
EP3831849A1 (en) | 2019-12-02 | 2021-06-09 | LamKap Bio beta AG | Bispecific antibodies against ceacam5 and cd47 |
AR121706A1 (es) | 2020-04-01 | 2022-06-29 | Hoffmann La Roche | Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap |
WO2021226440A1 (en) | 2020-05-08 | 2021-11-11 | Bolt Biotherapeutics, Inc. | Elastase-substrate, peptide linker immunoconjugates, and uses thereof |
CA3186059A1 (en) | 2020-08-13 | 2022-02-17 | Romas Kudirka | Pyrazoloazepine immunoconjugates, and uses thereof |
US20220195066A1 (en) | 2020-12-11 | 2022-06-23 | Bolt Biotherapeutics, Inc. | Anti-cea immunoconjugates, and uses thereof |
WO2022125891A2 (en) | 2020-12-11 | 2022-06-16 | Bolt Biotherapeutics, Inc. | Anti-cea immunoconjugates, and uses thereof |
EP4055055B1 (en) | 2020-12-18 | 2023-11-22 | LamKap Bio beta AG | Bispecific antibodies against ceacam5 and cd47 |
IL306114A (en) | 2021-03-26 | 2023-11-01 | Bolt Biotherapeutics Inc | 2-amino-4-carboxamide-benzazepine immunoconjugates and uses thereof |
WO2022204536A1 (en) | 2021-03-26 | 2022-09-29 | Bolt Biotherapeutics, Inc. | 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof |
AR126009A1 (es) | 2021-06-02 | 2023-08-30 | Hoffmann La Roche | Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam |
WO2023180489A1 (en) | 2022-03-23 | 2023-09-28 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigen |
WO2023242351A1 (en) | 2022-06-16 | 2023-12-21 | Lamkap Bio Beta Ag | Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
ATE120761T1 (de) | 1987-05-21 | 1995-04-15 | Creative Biomolecules Inc | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
GB9014932D0 (en) * | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
AU9052891A (en) | 1990-12-05 | 1992-07-08 | Novo Nordisk A/S | Proteins with changed epitopes and methods for the production thereof |
ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
DE69434447T2 (de) | 1993-06-07 | 2006-05-18 | Vical, Inc., San Diego | Für die gentherapie verwendbare plasmide |
AU723325B2 (en) | 1995-06-23 | 2000-08-24 | President And Fellows Of Harvard College | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors |
EP1724282B1 (en) | 1997-05-21 | 2013-05-15 | Merck Patent GmbH | Method for the production of non-immunogenic proteins |
PT1071752E (pt) | 1998-04-21 | 2003-11-28 | Micromet Ag | Polipeptidos especificos para cd19xcd3 e suas utilizacoes |
AU776910B2 (en) | 1998-12-08 | 2004-09-23 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Modifying protein immunogenicity |
RU2363707C2 (ru) | 2001-02-19 | 2009-08-10 | Мерк Патент Гмбх | Искусственные белки с пониженной иммуногенностью |
US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
US7820166B2 (en) | 2002-10-11 | 2010-10-26 | Micromet Ag | Potent T cell modulating molecules |
KR101229731B1 (ko) | 2003-10-16 | 2013-03-07 | 암젠 리서치 (뮌헨) 게엠베하 | 다중특이적 탈면역화된 cd3-바인더 |
US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
ITRM20030601A1 (it) * | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
JP5463036B2 (ja) * | 2005-12-21 | 2014-04-09 | アムゲン リサーチ (ミュンヘン) ゲーエムベーハー | 可溶性ceaに対する抵抗性を有する医薬抗体組成物 |
DK1976880T3 (en) | 2005-12-21 | 2016-09-26 | Amgen Res (Munich) Gmbh | Pharmaceutical compositions with resistance to soluble cea |
-
2006
- 2006-12-21 DK DK06841112.3T patent/DK1976880T3/en active
- 2006-12-21 LT LTEP06841112.3T patent/LT1976880T/lt unknown
- 2006-12-21 NZ NZ569204A patent/NZ569204A/en not_active IP Right Cessation
- 2006-12-21 US US12/158,611 patent/US8394926B2/en active Active
- 2006-12-21 RS RS20160791A patent/RS55181B1/sr unknown
- 2006-12-21 PT PT68411123T patent/PT1976880T/pt unknown
- 2006-12-21 ES ES06841112.3T patent/ES2595091T3/es active Active
- 2006-12-21 BR BRPI0620632-8A patent/BRPI0620632A2/pt active Search and Examination
- 2006-12-21 HU HUE06841112A patent/HUE031151T2/en unknown
- 2006-12-21 SG SG2013054853A patent/SG193141A1/en unknown
- 2006-12-21 JP JP2008546272A patent/JP5399712B2/ja not_active Expired - Fee Related
- 2006-12-21 ZA ZA200805400A patent/ZA200805400B/xx unknown
- 2006-12-21 WO PCT/EP2006/012425 patent/WO2007071426A1/en active Application Filing
- 2006-12-21 AU AU2006328886A patent/AU2006328886C1/en not_active Ceased
- 2006-12-21 EP EP12167996A patent/EP2527370A1/en not_active Withdrawn
- 2006-12-21 EP EP06841112.3A patent/EP1976880B1/en active Active
- 2006-12-21 KR KR1020087017796A patent/KR101287777B1/ko active IP Right Grant
- 2006-12-21 CA CA2633766A patent/CA2633766C/en not_active Expired - Fee Related
- 2006-12-21 PL PL06841112T patent/PL1976880T3/pl unknown
- 2006-12-21 CN CN200680052637.9A patent/CN101370827B/zh not_active Expired - Fee Related
- 2006-12-21 RU RU2008129787/10A patent/RU2426743C2/ru not_active IP Right Cessation
-
2008
- 2008-06-18 IL IL192277A patent/IL192277A/en not_active IP Right Cessation
- 2008-10-22 HK HK08111613.6A patent/HK1115890A1/zh not_active IP Right Cessation
-
2010
- 2010-11-29 RU RU2010148652/10A patent/RU2573893C2/ru not_active IP Right Cessation
-
2012
- 2012-10-03 JP JP2012221161A patent/JP2013056885A/ja not_active Withdrawn
-
2013
- 2013-01-14 US US13/740,358 patent/US9695250B2/en active Active
-
2016
- 2016-09-19 US US15/269,680 patent/US9982063B2/en active Active
- 2016-09-23 HR HRP20161216TT patent/HRP20161216T1/hr unknown
- 2016-09-23 CY CY20161100951T patent/CY1118053T1/el unknown
- 2016-12-21 ME MEP-2016-218A patent/ME02581B/me unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ME02581B (me) | Farmaceutski pripravci s otpornošću na topljivi cea | |
IL283205A (en) | Attached medicinal substance that binds to cells, preparations containing them and their uses | |
IL289165A (en) | Compounds with anticancer activity | |
HK1126975A1 (en) | Pharmaceutical compositions with enhanced stability | |
IL247741B (en) | Pharmaceutical preparations containing iron oxo-hydroxide, methods for their preparation and their uses | |
GB0603464D0 (en) | Improvements in & relating to external neurostimulation | |
ZA200807721B (en) | Anti-cancer pharmaceutical composition | |
GB0617191D0 (en) | Improvements in pharmaceutical compositions | |
IL192911A0 (en) | Compositions containing microalgae-derived polysaccharides and methods for the preparation thereof | |
ZA200905508B (en) | Compositions and methods to prevent cancer with cupredoxins | |
IL193706A0 (en) | Photoactive compounds and compositions and uses thereof | |
ZA200900199B (en) | Hard alloys with dry composition | |
IL197602A0 (en) | Compositions and methods to prevent cancer with cupredoxins | |
IL205966A0 (en) | Oligomer-tricyclic conjugates, compositions comprising the same and uses thereof | |
IL186337A0 (en) | Stannsoporfin compositions and administration | |
EP2119720A4 (en) | NEW VINBLASTINE DERIVATIVES, THEIR PREPARATION, APPLICATION AND PHARMACEUTICAL COMPOSITION CONTAINING SUCH DERIVATIVES | |
EP2124959A4 (en) | PHARMACEUTICAL COMPOSITION | |
GB0715428D0 (en) | Compositions and uses thereof | |
IL208567A0 (en) | Oligomer-aryloxy-substituted propanamine conjugates, compositions comprising the same and uses thereof | |
GB0701170D0 (en) | Compositions and uses thereof | |
EP1859804A4 (en) | AGAINST CANCER FOR COMBINATION WITH TELOMELYSIN | |
GB0701171D0 (en) | Compositions and uses thereof | |
IL247297A0 (en) | Medicinal compounds with resistance to soluble cea | |
GB0517043D0 (en) | Improvements in pharmaceutical compositions | |
GB0725264D0 (en) | Compositions and uses thereof |